Amgen Inc. (NASDAQ: AMGN) has posted some very highly anticipated and uninteresting earnings. The biotech giant reported $0.98 EPS net and $1.08 non-GAAP EPS on $3.31 billion in revenue, while Thomson Reuters had estimates of $1.15 in non-GAAP EPS and $3.63 billion in revenue.
Amgen is also trimming its forecast for 2009 to $4.55 to $4.75 non-GAAP EPS and $14.4 billion to $14.8 billion in revenues. Thomson Reuters estimates were $4.62 EPS and $14.9 billion in revenue for 2009. Unfortunately, this represents a drop from $15.003 billion in revenue from 2008.
The good news is that the net income was more than $1 billion for the quarter. Amgen also ended the quarter with $10.4 billion in cash and short-term instruments. The bad news is that there is no top-line growth. We have argued that Amgen is really just a drug stock stock that masquerades as a biotech stock. That is looking more and more the case today.
Shares of the biotech compnay traded up almost 4% at $46.82 today, but they are trading at $45.50 or so in the after-hours reaction.
With a 52-week trading range of $41.55 to $66.51, we aren’t ready to damn the company here because of its value proposition with $10 billion in cash and a forward earnings multiple of right around 10-times earnings. But with no growth, we can’t get excited either. We’d treat this as a coin toss now.
JON C. OGG
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.